ArticlePloS one2026
Cholesteatoma disease recidivism after canal wall up tympanomastoidectomy with or without obliteration (CLEAR-EAR): A protocol for a randomized controlled trial.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and rationaleCholesteatoma treatment relies on surgery with disease removal as the primary goal. While canal wall down (CWD) and canal wall up (CWU) tympanomastoidectomy remain standard approaches, mastoid obliteration has gained popularity. Canal wall up preserves ear canal anatomy and adding the obliteration technique suggests lower recurrence and residual rates. However, controversy persists and surgical consensus is lacking. Current decision-making relies on personal experience and patient-related factors rather than high-quality evidence. This study therefore investigates whether CWU with obliteration reduces cholesteatoma recurrence and residual disease compared to CWU without obliteration, by comparing recidivism rates for both interventions. Additionally, complications, hearing outcomes, quality of life and economic evaluation will be assessed. This study will assess long-term outcomes with a follow up of 5 years.
methodsThis multicentre single-blind randomized controlled trial (RCT) will include 178 adults undergoing CWU tympanomastoidectomy for cholesteatoma removal, randomized in a 1:1 ratio to CWU with obliteration or without obliteration. Recurrent or residual disease is assessed by micro-otoscopy at 6-18 weeks and by micro-otoscopy and DW-MRI at one, three, and five years postoperatively. Suspected disease is confirmed during revision surgery when indicated. Secondary outcomes include hearing, complications, quality of life, and economic evaluation. DISCUSSION: This is the first prospective RCT comparing CWU with and without obliteration. By establishing the follow-up period at five years, we aim to assess the true rates of recidivism, as literature indicates that most recurrent diseases are detected several years after surgery, with incidence appearing to rise approximately three years postoperatively. Key strengths include comparative hearing outcome assessment, quality of life evaluation, and economic evaluation. This multicentre trial aims to provide high-quality evidence to inform clinical guidelines and support evidence-based decision-making in cholesteatoma treatment.
trial registrationNetherlands Trial Register (CCMO): NL86362.041.24. Registered on 13 March 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.